A typical RSV season in the UK starts in October, peaks in December and declines by March.
A series of meetings of the JCVI RSV subcommittee have taken place in 2023.
evidence from manufacturers on the efficacy, safety and duration of protection of these immunisation products alongside clinical and epidemiological data on the burden of RSV in infants and older adults
ensuring high uptake in different population groups
London School of Hygiene and Tropical Medicine (LSHTM) has been used to inform JCVI’s advice
Cost effectiveness is a key factor in JCVI’s considerations to ensure that the finite resources of the health service are used to maximise the health of the population.
there is a significant burden of RSV illness in the UK population
JCVI advised that a RSV immunisation programme that is cost effective should be developed for both infants and older adults.
RSV infects up to 90% of children within the first 2 years of life and frequently reinfects older children and adults. For most people, RSV infection causes a mild respiratory illness. Babies under one year of age and the elderly are at the greatest risk of hospitalisation with more severe RSV
RSV accounts for approximately 33,500 hospitalisations annually in children aged under 5 years old. It is a leading cause of infant mortality globally, resulting in 20 to 30 deaths per year in the UK
The study aims to improve the understanding of the burden of RSV in infants and young children to provide data to inform future vaccination strategies.
Modellers at LSHTM developed a large dynamic transition model to try and characterize the transmission of RSV in England and Wales
An estimate of the burden from a synthesis of published studies was made to calculate quality adjusted life year (QALY) loss for a number of different health outcomes including symptomatic cases, hospital admissions and deaths. Annual estimates for GP hospitalizations and hospital bed days were used to estimate healthcare costs.
Results indicated RSV infections would account for the following number of infants less than 12 months old receiving the following treatments: nasogastric fluids: 11,000 IV fluids: 3,500 low flow oxygen: 11,000 high flow oxygen: 4,500 CPAP or BiPAP: 1,188 antibiotic prescriptions: 5,725
Glasp is a social web highlighter that people can highlight and organize quotes and thoughts from the web, and access other like-minded people’s learning.